Peptide hormones are powerful regulators of various biological processes. To guarantee continuous availability and function, peptide hormone secretion must be tightly coupled to its biosynthesis. A simple but efficient way to provide such regulation is through an autocrine feedback mechanism in which the secreted hormone is "sensed" by its respective receptor and initiates synthesis at the level of transcription and/or translation. Such a secretion-biosynthesis coupling has been demonstrated for insulin; however, because of insulin's unique role as the sole blood glucose-decreasing peptide hormone, this coupling is considered an exception rather than a more generally used mechanism. Here we provide evidence of a secretion-biosynthesis coupling for glucagon, one of several peptide hormones that increase blood glucose levels. We show that glucagon, secreted by the pancreatic α cell, up-regulates the expression of its own gene by signaling through the glucagon receptor, PKC, and PKA, supporting the more general applicability of an autocrine feedback mechanism in regulation of peptide hormone synthesis.
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gene expression | signal transduction P eptide hormones are powerful regulators of various biological processes, including gene expression, metabolism, cell cycle, motility, and apoptosis. To guarantee continuous availability of the hormone and thereby its function, hormone secretion must be tightly coupled to its biosynthesis. A simple but efficient way to provide such regulation is through an autocrine feedback mechanism in which the secreted hormone is "sensed" by its respective receptor and initiates synthesis at the level of transcription and/or translation. We and others have described such an autocrine feedback mechanism for the peptide hormone insulin in both rodent and human pancreatic β cells (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . After exocytosis of insulin, a portion of the secreted insulin binds to A-type insulin receptors and, by signaling via PI3 kinase, up-regulates (prepro)insulin gene transcription, which contributes to increased translation.
Given the unique role of insulin as the sole blood glucosedecreasing peptide hormone, it is unclear whether positive autocrine secretion-biosynthesis coupling is a unique phenomenon rather than a more generally used mechanism. We tested the more general role of an autocrine secretion-biosynthesis coupling using glucagon as an example. Glucagon is one of several peptide hormones that increase blood glucose levels. We show that glucagon, secreted by pancreatic α cells, up-regulates the expression of its own gene by signaling through the glucagon receptor, PKC, and PKA, supporting a more generalized applicability of an autocrine feedback mechanism in the regulation of peptide hormone synthesis.
Results and Discussion
Secreted Glucagon Up-Regulates Transcription of Its Own Gene and Renewed Synthesis of Glucagon. To test whether at all glucagon is able to up-regulate the expression of its own gene, we first stimulated mouse and human islets, as well as clonal glucagon-producing αTC1-9 cells, with exogenous glucagon at a glucose concentration that does not trigger glucagon exocytosis and then analyzed (prepro)glucagon mRNA levels. Stimulation of mouse and human islets for 15 min with 200 nM glucagon led to a greater than threefold increase in (prepro)glucagon mRNA levels by 60 min after the start of stimulation (Fig. 1A) . Similarly, a twofold increase in (prepro)glucagon mRNA levels was observed in αTC1-9 cells stimulated with exogenously applied glucagon (Fig.  1C) . The increase in (prepro)glucagon mRNA levels was only transient, however, and began to decline at 90 min after the start of stimulation in islets and by 120 min after the start of stimulation in αTC1-9 cells ( Fig. 1 B and C) .
To analyze the mechanisms underlying this positive feedback action in more detail, we performed a reporter gene assay in which expression of the red fluorescent protein DsRed2 was controlled by the rat glucagon promoter (−776/+7 bp). This allowed the analysis of stimulus-induced glucagon promoter activity in living α cells at the single-cell level. Similar to the dynamics described for insulin promoter-driven or c-fos promoter-driven DsRed2 expression/fluorescence in insulin-producing cells (12, 13) , DsRed2 fluorescence in glucagon-producing αTC1-9 cells began to increase by 60 min after the start of glucagon stimulation for 15 min and continued to increase up to 240 min (Fig. 1D) . The delayed onset of fluorescence increase is related to the time required for protein synthesis of DsRed2 and its maturation into a fluorophore (Fig. S1A) . The increase in fluorescence plateaus at 260 min, reflecting a decrease in glucagon promoter activity. A decline in fluorescence does not occur, owing to the long half-life of the fluorescent protein. In contrast to the glucagon promoter-driven expression, no increase in DsRed2 fluorescence was observed in control cells transfected with a cytomegalovirus (CMV) promoter-driven construct. Testing different concentrations of exogenously applied glucagon showed that stimulation with 100 pM glucagon for 15 min allowed maximal activation of the reporter gene (Fig. 1E) .
We next tested whether secretion of the hormone leads to upregulation of glucagon promoter activity. Glucagon-producing αTC1-9 cells secrete glucagon at glucose concentrations below 5 mM (14) (Fig. S1B ). Glucagon promoter activity was elevated under conditions that stimulated glucagon secretion (Fig. S1C) . Combining glucose-evoked glucagon secretion with immunoabsorption of secreted glucagon by anti-glucagon antibodies prevented the increase in glucagon promoter-driven DsRed2 expression, whereas application of a control IgG had no inhibitory effect (Fig. 1F) . Finally, we studied whether the positive feedback action of glucagon would lead to an increase in glucagon biosynthesis. Stimulation of αTC1-9 cells with either 1 mM glucose (which triggers secretion of glucagon) or exogenously applied glucagon (200 nM for 15 min) led to a 30% increase in glucagon biosynthesis within 60 min after the start of stimulation (Fig. 1G ).
Glucagon-Stimulated (Prepro)Glucagon Gene Transcription Requires
Signal Transduction via Glucagon Receptor, PKC, and PKA. Recent studies have characterized the expression and functionality of glucagon receptors in pancreatic α cells (15) (16) (17) . Our data from Western blot ( Fig. 2A ) and immunohistochemistry analyses (Fig.  2B ) confirm the presence of glucagon receptors in α cells in mouse and human pancreatic islets, as well as in glucagon-producing αTC1-9 cells. We next studied whether signal transduction through the glucagon receptor is required to elevate (prepro)glucagon mRNA levels by glucagon. Whereas stimulation with exogenous glucagon (200 nM for 15 min) led to an increase in mRNA levels in αTC1-9 cells and pancreatic islets, the stimulatory effect of glucagon on the transcription of its own gene was abolished when cells or islets were treated with 400 nM glucagon receptor antagonist II (GRA II) ( Fig. 2 C and D) . Similarly, treatment with GRA II abolished the stimulatory effect of exogenous glucagon ( Fig. 2E) , as well as that of secreted glucagon after stimulation with 1 mM glucose (Fig. 2F ), on glucagon promoter activity. Finally, pretreatment of αTC1-9 cells with 1 μM [des-His1, Glu9] glucagon amide, a glucagon analog that binds to but does not activate the glucagon receptor, abolished glucagon-stimulated activation of the glucagon promoter (Fig. 2G) .
Signaling cascades that can be triggered by the glucagon receptor activate PKA via the adenylate cyclase system and activate PKC via the phospholipase C system (18, 19) . We next analyzed whether exogenously applied or secreted glucagon activates either PKA or PKC. Stimulation with either exogenous glucagon (200 nM for up to 15 min) or secreted glucagon at low glucose concentration (1 mM glucose for up to 15 min) led to a more than twofold elevation in PKA activity (Fig. 3A) and to a more than threefold increase in PKC activity (Fig. 3B ). Of note, the increased activity of both kinases was transient, and activity returned to basal levels by 30 through either PKA or PKC is involved in glucagon-stimulated (prepro)glucagon gene transcription, we used Rp-cAMPS and bisindolylmaleimide-I (BIM) as pharmacologic inhibitors of PKA and PKC, respectively. Treatment of αTC1-9 cells with either 100 μM Rp-cAMPS or 150 nM BIM abolished the glucagonstimulated increase in (prepro)glucagon mRNA levels (Fig. 3C) , as well as glucagon promoter activity (Fig. 3D) . Finally, treatment of mouse and human pancreatic islets with either inhibitor drastically reduced the stimulatory effect of exogenous glucagon on the transcription of its own gene (Fig. 3E) .
Glucagon-Stimulated Glucagon Gene Transcription Is Mediated via cAMP-Element Binding Protein. The promoter of the (prepro)glucagon gene is well characterized, and cis-and transacting factors that contribute to transcriptional control have been identified (20) . Among these transcription factors, the prime candidates for glucagon-stimulated transcriptional control are the cAMPresponse element (CRE) (21) and the respective CRE-binding protein (CREB), which generally can be activated by PKA and PKC (22, 23) . CREB has been shown to be activated in response to glucagon stimulation in hepatocytes and pancreatic β cells (24, 25) . To test whether the positive autocrine feedback action by glucagon on the transcription of its own gene involves CREB, we mutated the CREB binding site in the glucagon promoter of our reporter construct. Mutating the CRE motif from TGACGTCA to TGTGGTCA (CRE-mut; Fig. 4A ) abolished binding of CREB to respective ds oligonucleotide probes in electrophoretic mobility shift assays (Fig. 4B) . The CREB/ds oligonucleotide complex (complex 1) was identified by "supershifting" this complex in response to incubation with an anti-CREB antibody, which resulted in the formation of complex 2 (Fig. 4B) . Introduction of the same mutation into the CRE motif of our reporter construct reduced basal glucagon promoter activity (Fig. 4C) , and also abolished the stimulatory effect of secreted glucagon (Fig. 4D ) and exogenously applied glucagon (Fig. 4E ) on glucagon promoter-driven DsRed2 expression/fluorescence.
Conclusion
Positive autocrine feedback leading to a secretion-biosynthesis coupling, which allows replenishment of the peptide hormone stores of the hormone-producing cell, is not a widely accepted concept. Such a feedback mechanism has been reported for the peptide hormones insulin (1-11) and gastrin (26), as well as for the cytokines IL-1 (27) , IL-21 (28) , and erythropoietin (29) ; growth factors HGF, KGF, and kit (30) ; and the vasoconstrictor endothelin (31, 32) .
Our data demonstrate that secreted glucagon stimulates its own resynthesis via a positive autocrine feedback mechanism. The increase in (prepro)glucagon mRNA levels is only transient, however, and the feedback loop is turned off by a lack of glucagon stimulus, leading to transient activation of protein kinases PKA and PKC in response to rising blood glucose levels, as well as to inhibition of glucagon gene transcription by insulin (33) . Interestingly, GLP-1, another product of the (prepro)glucagon gene that is synthesized and secreted by intestinal L cells, is also able to activate the glucagon promoter in αTC1-9 cells (Fig. S2) .
Although the presence of all involved players in pancreatic α cells has been documented in earlier studies-that is, the presence in α cells of glucagon receptor (15) (16) (17) and the roles of CRE and CREB (21, 34, 35) and of cAMP, PKC, and PKA (35) (36) (37) (38) in (prepro)glucagon gene expression-their involvement in glucagonstimulated (prepro)glucagon gene expression had not been studied previously. There may be two major reasons for this. First, a mouse model with a general knockout of the glucagon receptor showed an increase in circulation glucagon levels as well as increased pancreatic glucagon content (39) . However, it should be stressed that under conditions of "global glucagon resistance," the increased demand for glucagon is compensated for by an increase in α cell mass, as well as glucagon biosynthesis. The involved signaling mechanisms "override" regulatory circuits that function under physiological conditions. The fact that signaling and function of α cells under these conditions is not physiological is underscored by the finding that the α cells in this mouse model show an immature phenotype expressing genes normally repressed in mature α cells, such as genes encoding GLUT2 or Pdx1 (40) . A second reason for the lack of previous studies may be the "textbook wisdom" suggesting that the existence of a positive autocrine feedback mechanism for peptide hormone biosynthesis is counterintuitive, because elevated/continuous exposure to a peptide hormone leads to desensitization to the hormone at the effector cell level, and, consequently, cells that produce and secrete a peptide hormone should be desensitized to the hormone because of its continuous presence. However, it should be kept in mind that a broad spectrum of fuel-regulating hormones, including insulin and glucagon, are secreted in a pulsatile manner (41, 42) . Along with being sensed more potently by peripheral target cells, pulsatility also provides an off state of ligand presence for the hormone-secreting cells themselves, thereby allowing hormone sensing.
Although our data indicate the contribution of CREB to the glucagon autocrine feedback mechanism, we do not exclude the possible involvement of other transcription factors that can be activated by PKA and PKC. Moreover, given that synthesis of peptide hormones must be coupled to the highly complex regulated biosynthesis of secretory granules, as for insulin (43), we do not exclude the possible existence of further retrograde signaling mechanisms.
In conclusion, together with previously published data on insulin and gastrin feedback, the present data on glucagon support the concept of positive autocrine feedback action as a more general mechanism involved in the secretion-biosynthesis coupling of peptide hormones.
Materials and Methods
Pancreatic islets were prepared from 4-mo-old BALB/C mice using collagenase digestion as described previously (44) . Human islets were provided by O. Korsgren (Department of Oncology, Radiology, and Clinical Immunology, Uppsala University Hospital, Uppsala, Sweden) via the Nordic Islet Network. The glucagon promoter (−773/+35 bp) was amplified by PCR from genomic rat DNA using 5′-TCCTTCTGTTGAATGGCCAG-3′ as the upstream primer and 5′-TTTGAGTGTGTTCTGCGCC-3′ as the downstream primer. Total RNA was purified from 20 islets using the RNeasy Micro Kit (Qiagen) according to the manufacturer's instructions. Reverse-transcription reactions were performed using the SuperScriptIII Kit (Invitrogen).
(Prepro)glucagon mRNA levels were determined by real-time PCR. Taqman reactions were carried out following the manufacturer's instructions for Taqman gene expression assays (Applied Biosystems). Relative quantification of glucagon mRNA expression was calculated by the comparative Ct method (45) using peptidylpropyl isomerase A as an internal reference. Glucagon secretion was measured using the LINCO glucagon RIA kit (Millipore). Total protein content of the cell lysate, determined by the Bradford assay, was used to normalize for between well variations in cell density. Glucagon biosynthesis was analyzed by using L- [4,5- 3 H] leucine (PerkinElmer) for labeling and a sheep polyclonal antibody directed toward the C terminus of glucagon (ab36215; Abcam) for immunoprecipitation. Nuclear extracts from αTC1-9 cells for EMSA were prepared as described previously (46) . Supershift assays were performed using a CREB-antibody (Abcam). The following inhibitors were used: PKA inhibitor Rp-cAMPS, PKC inhibitor BIM I, glucagon In C, αTC1-9 cells were cotransfected with pGL4.CMV.hRlucCP and either WT pGlcg1.luc2neo (CRE) or mutant pGlcg1.CRE-mut.luc2neo (CRE-mut). Basal promoter activity was analyzed as described in Materials and Methods and calculated by dividing Glcg1.CRE or Glcg1.CRE-mut promoter-controlled firefly luciferase luminescence by CMV promoter-controlled Renilla luciferase luminescence. Glucagon promoter activity is presented as percentage of WT promoter activity (given as 100%); n = 3. Data are expressed as mean ± SEM; *P < 0.05. In D and E, αTC1-9 cells were transfected with either WT pGlcg1.DsRed2 (CRE) or mutant pGlcg1.mut.DsRed2 (CRE-mut). Cells were left unstimulated or were stimulated with either 1 mM glucose (D) or 200 nM glucagon (at 16.7 mM glucose) (E) for 15 min. Data represent the ratio of DsRed2 fluorescence values obtained at 240 min and 60 min and are expressed as mean ± SEM for at least 15 monitored cells. Significance vs. stimulated expression of CRE, *P < 0.05.
